AGLE - Aeglea again pushes back arginase 1 deficiency trial enrollment to March

Aeglea BioTherapeutics ([[AGLE]] -4.8%) disclosed updated guidance on the enrollment completion of its Phase 3 PEACE trial evaluating pegzilarginase in patients with arginase 1 deficiency (ARG1-D).Citing COVID-19 related disruptions, the company expects to complete enrollment by the end of March vs. January end as expected earlier, with topline data anticipated in Q4 of 2021, compared to mid-2021.To date, the company has enrolled 22 patients, or ~75% of the targeted trial enrollmentARG1-D is characterized by the buildup of arginine and ammonia in the body due to the lack of an enzyme called arginase. Untreated children experience seizures, spasticity, short stature and intellectual disability.Pegzilarginase, an enzyme replacement therapy, is an enhanced human arginase that breaks down arginine.

For further details see:

Aeglea again pushes back arginase 1 deficiency trial enrollment to March